INTRODUCTION
Since its discovery in the mid-1980s, MET, the receptor of hepatocyte growth factor (HGF), has been found to be very important in embryonic development, cell migration, cell growth, cell survival, epithelial-mesenchymal transition, wound healing and tumorigenesis (1) (2) (3) . Activation of MET has been found in various cancers, including bladder, breast, cervical, colorectal, gastric, kidney, liver, lung, ovarian and prostate (1) . MET amplification has also been found to be an important mechanism for acquired resistance to anti-EGFR therapies in non-small cell lung cancer (4, 5) . Because of the important roles of HGF-MET signaling in various cancers, many inhibitors targeting this pathway are currently being developed for clinical applications, including both small-molecule inhibitors and monoclonal antibodies (3) . A humanized one-armed anti-MET antibody, onartuzumab (MetMAb), has been evaluated in clinical trials for advanced non-small cell lung cancer in combination with erlotinib. While patients with MET positive tumor benefited from such combination treatment, the MET negative patients actually had worse overall survival when treated with onartuzumab plus erlotinib, compared to with erlotinib plus placebo (6) . Such results emphasize the importance to evaluate MET expression level for patient stratification to improve these anti-MET therapies.
Compared to traditional biopsy and immunohistochemistry, antibody based positron emission tomography, or immunoPET, offers a unique opportunity for non-invasive 6 evaluation of the in vivo expression levels of various biomarkers. The whole body information provided by immunoPET scans can help illuminate the heterogeneity of the primary tumor and metastatic lesions, and the evolving molecular status of tumors can be easily monitored via serial immunoPET scans to aid treatment planning and follow-up (7) . Previously, anti-MET immunoPET imaging has been successfully demonstrated in preclinical mouse models using the intact monoclonal mouse antibody DN-30 or the humanized one-armed antibody onartuzumab (8, 9) . However, these antibodies with full Fc domains require relatively long imaging delays (3 days to 1 week) to clear from the circulation in order to produce high contrast images.
By using smaller antibody fragments with shorter serum half lives, such as diabodies and minibodies (described in greater detail below), immunoPET can be performed at earlier time points with similar or even higher contrast, highly desired for clinical imaging applications (7, (10) (11) (12) . Compared to an intact antibody (150 kDa) with heavy and light chain variable and constant domains, a single-chain variable fragment (scFv; ~27 kDa) is a small monovalent fragment consisting of the antibody V H and V L domains linked by a flexible linker. A diabody is related to an scFv, comprised of only the V H and V L domains, but with a shorter linker that induces dimerization, resulting in a bivalent fragment (~55 kDa). The bivalent minibody fragment is formed by fusion of the scFv to the immunoglobulin C H 3 constant domain for dimerization. Their higher molecular weight (~80 kDa) promotes longer serum persistence, facilitating higher uptake levels in target tissues. Cys-diabodies are modified diabodies with engineered cysteines at 7 their C-termini to allow site-specific conjugation and labeling (13) (14) (15) (16) (17) (18) . Figure 1 shows sizes and structures of these antibody fragments in comparison with an intact antibody.
The availability of engineered antibody fragments allows selection of the optimal format for an imaging probe based on the target and application.
For clinical use, fully human antibodies and their respective fragments are preferred due to the lower risk of immunogenicity, and phage display technology offers a reliable source of high affinity fully human antibodies (19) (20) (21) . With FDA approved Humira (adalimumab) and Benlysta (belimumab), and dozens more in clinical trials (22) , phage display technology is now one of the major sources of fully human monoclonal antibodies for therapeutic applications. Furthermore, because the human antibody gene sequences are already in hand, reformatting selected scFvs into diabodies or minibodies is very fast and simple. This approach has been employed to generate several previous antibody fragment imaging probes from phage libraries (16, 23, 24) .
As immunoPET is playing an increasingly important role in diagnosis, and in the development and implementation of targeted therapies (25, 26) , phage display can be an effective path for the rapid generation of antibody fragment-based imaging probes.
Instead of the months required to generate and screen conventional hybridomas, isolate the antibody genes, humanize, and conduct affinity maturation, by using phage display technology, fully human antibodies can be identified and reformatted in just a few weeks. This can lead to significantly faster discovery and development of novel antibodies and fragments for various applications.
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In this study, we utilized a previously reported fully human scFv phage display library (27) to screen for novel human antibodies recognizing human MET. One of the antibody clones, H2, was reformatted into a cys-diabody and a minibody for MET-specific immunoPET studies in mouse models to evaluate the potential of assessing MET expression levels in vivo. In parallel, the potential biological activity of the human anti-MET antibodies was assessed, since avoidance of agonistic biological activity is desirable in an imaging agent. 
MATERIALS AND METHODS
Details of antibody reformatting, expression and purification, radiolabeling of antibody fragments and the immunoreactivity assay can be found in the supplementary methods.
Cell lines and tumor models
Hcc827 parental cells and the gefitinib resistant Hcc827-GR6 cells (4) 
Phage library selection
A naïve human scFv phage display library from James D. Marks' laboratory (UCSF) (27) was used to perform three rounds of selection against recombinant human MET protein using previously published method (28) . Briefly, recombinant MET protein was used to coat an immunotube (Nunc). After washing and blocking, the immunotube was then incubated with 10 12 ~10 13 phage in 2 mL 1% milk-PBS for 2 hours at room temperature. The unbound phage were washed off with PBS and 0.05% PBS-Tween, and the bound phage were eluted with 1 mL of 100 mM triethylamine for 8 minutes and neutralized with 0.5 mL of 1 M Tris-HCl (pH = 7.5). The eluted phage were used to infect exponentially growing E. coli TG1, and the infected bacteria were then used to produce phage for the next round of selection. 100 µg of MET protein from R&D Systems (358-MT/CF) was used for the first round. Reduced amounts of MET protein from another supplier (Sino Biological Inc., 10692-H08H) were used for the following 2 rounds.
ELISA
Phage ELISA was performed as previously described (28) 
In vitro MTS assay
Cell growth and inhibition were evaluated by MTS assay using the CellTiter96 using a filtered backprojection algorithm, and analyzed with AMIDE software. Ex vivo biodistribution studies were performed after the final imaging time point. Organs, tumors and blood were harvested and weighed, and the radioactivities were measured by gamma counting. The percent injected dose per gram of tissue (%ID/g) was calculated after decay correction to evaluate the uptake level in each organ. About half of the Hcc827-GR6 tumors were cystic, and the biodistribution of these tumors was calculated excluding the cystic fluid. The radioactivities of some kidney samples were too high to be accurately measured by gamma counting, so the uptake levels were estimated by image quantitation using previously described method (29) .
Pharmacokinetic studies 89 Zr labeled H2 cys-diabody (22 
the cys-diabody clones, C2, H2 and H5, were successfully expressed, purified (yields ranging from 1 to 3 mg/L, stable at 4 °C for months) and characterized further. Other clones were dropped because of low expression level and purity.
In vitro characterization of cys-diabodies
The purified C2, H2 and H5 cys-diabodies retained the ability to bind to MET protein.
Cross reactivity analysis showed that the H2 cys-diabody clearly bound to both human and mouse MET, while C2 and H5 have no significant cross reactivity to the mouse MET ( Figure 2D ). Binding curves on Hcc827-GR6 showed H2 cys-diabody has the highest binding affinity (K D = 0.73 ± 0.10 nM), while the other two cys-diabodies also have low nanomolar affinities, as shown in Figure 2E .
Cell growth inhibition assays
To assess off-target toxicity, first, the parental Hcc827 cells were treated with cys-diabodies alone for 3 days in culture media. No significant effects were observed overall, but the H5 cys-diabody appeared to have a small activating effect at very high concentration (180 nM) ( Figure 3A) , which might also be due to experimental variation.
Next, the cys-diabodies were used to treat two gefitinib-resistant cell lines lacking MET amplification, H1650 and H1975, in combination with gefitinib. No significant inhibitory effects were observed on these two cell lines ( Figure 3B significant, and the mean cell activities were all very similar to the no antibody group. C2 showed a slight activating effect on the H1650 cell line as the cys-diabody concentration was increased..
The anti-MET inhibitory effects were tested by applying these cys-diabodies to two cell lines with amplified MET signaling, Hcc827-GR6 and Hcc827-/+. The Hcc827-GR6 cell line was generated through prolonged selection from the parental Hcc827 treated with gefitinib (4). The Hcc827-/+ cells were obtained by short-term treatment of Hcc827 with HGF and erlotinib (see Materials and Methods). Figure 3C shows the H2 cys-diabody has the strongest inhibitory effect at lowest concentration, while C2 and H5 only showed inhibitory effects at higher concentrations. Because of the high affinity and inhibitory effect of H2 cys-diabody, we further reformatted H2 into a minibody and expressed the H2 minibody in 293F cells. The protein A purified H2 minibody was then tested for inhibitory effects on Hcc827-GR6 in comparison with the cys-diabody and scFv. Similar inhibitory effects were observed for the minibody as shown in Figure 3D .
Internalization and uptake of 89 
Zr labeled H2 cys-diabody
Following site-specific conjugation of H2 cys-diabody with maleimide-DFO and radiolabeling with 89 Zr (Figure 4A ), the labeling efficiency was 49%, the radiochemical purity was 95% after column purification, and the specific activity was 0.13 MBq/µg.
When MET expressing Hcc827-GR6 cells were cultured with excess radiolabeled H2 cys-diabody, the membrane bound radioactivity decreased in the first 6 hours while the internalized activity increased, giving a constant total cell radioactivity in the first few hours. The membrane radioactivity remained low and the internalized 89 Zr activity continued to accumulate over the 24 hour time course ( Figure 4B ). Such results indicate rapid internalization of the radiolabeled H2 cys-diabody, making it necessary to use residualizing isotope to achieve better imaging results. 89 Zr labeled H2 cys-diabody ( 89 Zr-DFO-H2 cys-diabody) was initially used for immunoPET studies in mice bearing MET positive tumors (Hcc827 or Hcc827-GR6) and MET negative C6 tumors. 89 Zr-DFO-H2 cys-diabody showed specific uptake in antigen positive tumors (Hcc827, Hcc827-GR6) and high contrast images were obtained at as early as 4 hours post injection. As shown in Figure 4C Table 1 summarizes the ex vivo biodistribution study of the H2 cys-diabody imaging. The kidney uptakes were not shown in the biodistribution results because the signals were too high to be accurately measured by the gamma counter. However, we estimated the uptake levels to be about 83 -104 %ID/g (Hcc827 vs. C6 group: 85 ± 1 %ID/g; Hcc827-GR6 vs. C6 group: 99 ± 2 %ID/g; Hcc827-GR6 vs. Hcc827 group: 98 ± 9 %ID/g) by image quantitation using a previously described method (29) . The high kidney uptakes are due to the renal clearance of these low molecular weight cys-diabody proteins.
In vivo PET imaging and ex vivo biodistribution
To further confirm the specificity of anti-MET targeting, H2 minibody was also evaluated in immunoPET studies. For the minibody imaging, tumor bearing SCID mice were scanned at 24 hours and 44 hours post injection. Figure 4F However, the image contrast was not improved due to higher background signal in the blood (Hcc827-GR6 Tumor : Blood = 4.2 ± 0.5, details shown in Table 2 ). To further compare the pharmacokinetic properties, radiolabeled H2 cys-diabody and minibody were also injected into tumor-free female SCID mice, and their terminal half lives were estimated to be 24 ± 3 min (n=2) and 10 ± 1 h (n=4) respectively. 
DISCUSSION
In this work, we isolated multiple anti-MET antibody clones from a large naïve human scFv phage display library. Three of these clones were successfully reformatted into cys-diabodies for in vitro characterization, and demonstrated high affinities ranging from 0.7 to 5.1 nM. The H2 cys-diabody shows the highest affinity (K D = 0.73 ± 0.10 nM), best anti-MET inhibitory effect (significant inhibitory effects at 1.8 nM on MET dependent cells, p < 0.01), and cross-reacts with murine MET. ImmunoPET studies using 89 Zr radiolabeled H2 cys-diabody and minibody were able to distinguish a MET over-expressing gefitinib resistant tumor from the parental tumor at as early as 4 hours post injection. The ex vivo biodistribution analysis also showed significant differences in tracer uptake levels in the MET over-expressing Hcc827-GR6 tumors vs. the parental tumors (p < 0.01). Using the H2 cys-diabody, very high positive tumor-to-blood ratios (18 to 22) were achieved at 20 hours post injection. These results indicate the potential for rapid and even same day imaging for patient stratification. 
selection. During the phage selection process, high affinity candidates are not always the most enriched ones. Individual antibody sequences can vary in the ability to be expressed, or may encode proteins that are toxic or inhibit robust growth of the host bacterium. Rare clones may express antibodies that perform better in vivo due to unique pharmacokinetic properties and stability. Complementary to the more traditional medium-throughput approach we used in this study, high-throughput approaches empowed by deep sequencing, low-cost gene synthesis, and high-throughput protein production technologies can enable researchers to screen higher numbers of candiates. This will make the rare clones more accessible to reasearchers, including clones with unique properties. For example, although anti-tumor effects are desirable for therapeutic applications, it is typically preferable to employ biologically inert binders for strictly imaging applications. The ability to screen and evaluate larger numbers of candidate clones would increase the odds of finding the best fit for specific applications.
While the intent was to isolate antibody fragments for in vivo PET imaging, it was also important to avoid antibodies that may stimulate MET signaling. Given the fact that H2 cys-diabody is rapidly internalized upon binding to cell surface MET, a residualizing radiolabeling approach using chelated 89 Zr was selected, the same as two previous preclinical anti-MET immunoPET studies (8, 9) . It is difficult to directly compare among these studies because of the differences in tumor models and mouse strains. However, it is known that radiolabeled diabodies usually have lower tumor uptake levels compared to larger fragments or intact antibodies, but high contrast images can be produced at earlier time points, due to the rapid blood clearance (34) . With the high tumor-to-blood ratio (~20:1) at only 20 hours post injection, these results once more demonstrated the unique advantage of diabodies for rapid and high contrast immunoPET imaging. Thus far, anti-MET imaging studies using similar small antibody fragments in patients have not been described, motivating the current efforts to develop these fully human antibody fragments for in vivo PET imaging. Previously, Santimaria et al. had demonstrated diabody-based imaging of the ED-B fibronectin domain in patients (35) . Due to the fast clearance of the diabody fragment, they were able to demonstrate tumor targeting at as early as 6 hours post injection instead of the 4 -7 day delay typically required when imaging with intact antibodies (7) . With the short serum half lives of the H2 antibody fragments, similar rapid imaging in patients can be expected in the future.
In the current cys-diabody imaging studies, some variations were observed between experiments. For example, the cys-diabody imaging of mice bearing dual Hcc827-GR6 and Hcc827 tumors showed higher tumor uptake levels relative to the other experiments. This may reflect the effects of variations in radiolabeling, tail vein injection, or perhaps the ages of the mice and variations in physiology. Despite difference in absolute uptake levels, the tumor-to-blood ratios remain similar among Table 1 . Ex vivo biodistribution of 89 Zr-DFO-maleimide-H2 cysDb at 20 hours post injection in female SCID mice bearing MET-positive (Hcc827, Hcc827-GR6) and MET-negative (C6) tumors. 89 Zr-DFO-maleimide-H2 cysDb at 44 hours post injection in female SCID mice bearing Hcc827 and Hcc827-GR6 tumors. 
